CalciMedica Registers Resale of 56M Shares from June Private Placement
CALC sits 65% above its 52-week low of $0.461 on light trading volume (0.2× avg).
Summary
CalciMedica filed an S-3 to register the resale of 56 million shares from its June 2026 private placement, enabling investors to sell. The registration makes the overhang tradable at a time when the stock trades below the placement price and the company faces a reverse split vote to avoid delisting.
Key Events · Financing and Capital Events · CALC
-
Resale Registration Filed
CalciMedica registered the resale of 56,020,287 shares from its June 2026 private placement, consisting of 14.9M common shares, 3.7M pre-funded warrant shares, and 37.3M shares underlying Series A and B warrants.
-
Overhang Becomes Tradable
The registration enables selling stockholders to dispose of shares, creating potential selling pressure. The 56M shares represent a significant overhang relative to the 30.7M shares outstanding.
-
Pricing Below Placement Cost
The registration uses a proposed maximum offering price of $0.73 per share, below the $0.8033 unit price paid in the June placement, reflecting the stock's decline.
-
Reverse Split Vote Looms
The filing comes as CalciMedica seeks stockholder approval for a reverse stock split to maintain Nasdaq listing, adding to the dilution and overhang concerns.
Analysis · CALC · Life Sciences
This S-3 registers the resale of 56,020,287 shares issued in the June 2026 private placement, making the overhang tradable. The registration is a required follow-through under the purchase agreement, but it quantifies the potential selling pressure: up to 56 million shares, representing a substantial portion of the current 30.7 million outstanding. While the company receives no proceeds from resales, the filing enables investors to exit, which could weigh on the stock. The offering price of $0.73 per share (based on recent market prices) is below the $0.8033 unit price paid in the placement, reflecting the stock's decline since June. The filing also highlights the pending stockholder vote for a reverse split to maintain Nasdaq listing, adding to the overhang narrative.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.4M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.